Can I Take Resveratrol with Tresiba (Insulin Degludec)?

What Is Tresiba and Why Does the Interaction Question Matter?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin analog approved by the FDA in September 2015 for adults and children aged one year and older with type 1 or type 2 diabetes. Its distinguishing pharmacokinetic feature is a half-life of approximately 25 hours, nearly twice as long as insulin glargine U-100, which produces a flat, stable 24-hour action profile with lower day-to-day glucose variability than older basal insulins.

The DEVOTE trial (N=7,637) compared insulin degludec with insulin glargine U-100 in high-cardiovascular-risk type 2 diabetes patients over a median of two years. Degludec produced a 40% lower rate of severe hypoglycemia (hazard ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) without sacrificing glycemic control. That trial established degludec's favorable safety profile for severe hypoglycemia under standard conditions, but it did not evaluate concurrent supplement use.

Because insulin degludec acts continuously and cannot be "turned off" the way a short-acting bolus insulin can, any supplement that augments its glucose-lowering effect compounds hypoglycemia risk in a sustained, difficult-to-reverse way. That is why the resveratrol question deserves careful attention.

1

What Is Resveratrol and What Does It Do to Blood Glucose?

Mechanism of Glucose-Lowering Action

Resveratrol (3,5,4-trihydroxy-trans-stilbene) is a naturally occurring polyphenol concentrated in grape skins, red wine, and Japanese knotweed (Polygonum cuspidatum). Supplement doses typically range from 150 mg to 1,000 mg per day, far exceeding what is achievable through diet alone.

Its glucose-lowering mechanisms are multiple and partially independent. First, resveratrol activates SIRT1 (sirtuin-1) and AMP-activated protein kinase (AMPK), both of which improve skeletal-muscle glucose uptake independently of insulin signaling. Second, it reduces hepatic glucose output by suppressing gluconeogenic gene expression. Third, in animal models it improves beta-cell insulin secretion, though this effect is less consistent in human trials.

2

Evidence from Human Trials

A randomized, double-blind crossover trial by Brasnyó et al. (N=19 type 2 diabetes patients) published in the British Journal of Nutrition found that resveratrol 5 mg twice daily for four weeks significantly reduced insulin resistance as measured by the homeostatic model assessment (HOMA-IR), with P<0.05 versus placebo. That is a very low dose; many commercial supplements contain 200 to 500 mg per capsule.

A 2020 meta-analysis published in Nutrition and Metabolism (pooled N=711 participants across 17 RCTs) reported that resveratrol supplementation reduced fasting blood glucose by a mean of 4.87 mg/dL and fasting insulin by 1.43 µIU/mL compared with placebo. The effect was larger in trials using doses above 500 mg/day and in patients already on antidiabetic therapy.

3 4

The Key Takeaway for Tresiba Users

A supplement that independently lowers fasting glucose and insulin resistance, added to an ultra-long-acting insulin with a 25-hour half-life, creates a sustained additive pharmacodynamic effect. The risk is not theoretical.

Pharmacokinetic Interaction: What Happens to Tresiba's Metabolism?

CYP3A4 and Insulin Degludec

Insulin degludec is not metabolized by cytochrome P450 enzymes. Like other insulins, it is broken down via protease-mediated degradation, primarily in the liver, kidney, and muscle. That means CYP3A4 inhibition by resveratrol does not directly alter insulin degludec's clearance or plasma levels.

However, resveratrol's CYP3A4 inhibition does matter if you take other medications alongside Tresiba. Drugs metabolized by CYP3A4, including some statins, certain calcium-channel blockers, and oral antifungals, may accumulate to higher plasma levels when resveratrol is co-administered. If those drugs also affect glucose metabolism (as some statins do), indirect effects on glycemic control are possible.

5

CYP2C9 Consideration

Resveratrol also inhibits CYP2C9, the enzyme responsible for metabolizing sulfonylureas such as glipizide and glibenclamide. Patients on Tresiba who also take a sulfonylurea face a two-pronged hypoglycemia risk: the direct pharmacodynamic effect of resveratrol on blood glucose plus elevated sulfonylurea plasma levels due to reduced CYP2C9 clearance. This combination warrants extra caution and likely requires a sulfonylurea dose review before starting resveratrol.

6

Pharmacodynamic Interaction: The Additive Hypoglycemia Risk

How the Two Work Together

Tresiba provides continuous basal insulin coverage. Resveratrol adds an independent glucose-lowering signal through AMPK activation and improved peripheral insulin sensitivity. When both are active simultaneously, total glucose-lowering effect exceeds what either agent produces alone.

The clinical consequence is hypoglycemia. Symptoms of hypoglycemia include diaphoresis, tremor, confusion, palpitations, and, in severe cases, loss of consciousness. Because insulin degludec has such a long duration of action, a hypoglycemic episode driven partly by resveratrol may last longer and require more glucose supplementation to correct than an episode driven by a shorter-acting insulin.

Dose Dependency

The magnitude of resveratrol's glucose-lowering effect appears dose-dependent. At doses of 150 to 250 mg/day, the effect on fasting glucose in most human trials is modest (1 to 3 mg/dL reduction). At doses of 500 to 1,000 mg/day, reductions of 5 to 10 mg/dL have been reported in patients already on antidiabetic therapy. For a Tresiba patient already near their fasting glucose target of 80 to 130 mg/dL (per the American Diabetes Association 2024 Standards of Care), a 5 to 10 mg/dL additional reduction could push glucose into hypoglycemic range.

7

What the ADA Guidelines Say About Supplements

The 2024 ADA Standards of Medical Care in Diabetes state directly: "Evidence does not support recommending dietary supplements, vitamins, minerals, herbs, or spices for people with diabetes who do not have underlying deficiencies... Routine supplementation with antioxidants, such as vitamins E and C and carotene, is not advised due to lack of evidence of efficacy and concern related to long-term safety."

While resveratrol is not explicitly named in this passage, it falls within the antioxidant polyphenol category under the same caution. The ADA guidelines do not endorse resveratrol as adjunct therapy for diabetes management.

8

Resveratrol's Estrogenic Activity and Insulin Sensitivity

Weak Estrogen Receptor Binding

Resveratrol acts as a phytoestrogen. It binds estrogen receptor beta (ER-beta) with modest affinity and can modulate estrogen-responsive gene expression. This property is what prompts some researchers to classify resveratrol as an "estrogenic" compound, and it has implications for insulin sensitivity.

Estrogens generally improve insulin sensitivity in women. In postmenopausal women with type 2 diabetes, endogenous estrogen decline contributes to worsening insulin resistance. Resveratrol's weak estrogenic action could theoretically improve insulin sensitivity in this population, amplifying the pharmacodynamic overlap with Tresiba.

9

Practical Relevance

For most patients, this effect is probably minor compared to resveratrol's direct AMPK-mediated mechanism. Still, postmenopausal women on Tresiba taking high-dose resveratrol (500 mg/day or above) represent a subgroup where glucose monitoring should be particularly thorough during the first four to six weeks of co-administration.

Does Timing or Dose Separation Reduce the Risk?

Why Dose Separation Does Not Solve the Problem

For drug interactions that are purely pharmacokinetic, separating doses by two to four hours can meaningfully reduce the magnitude of the interaction. The resveratrol-Tresiba interaction is primarily pharmacodynamic, meaning both agents are acting on the same physiological target (blood glucose regulation) through independent mechanisms. Separating the timing of a resveratrol capsule from a Tresiba injection does not reduce the overlap in their biological effects.

Tresiba is injected once daily and acts for approximately 42 hours, overlapping into the next day's dosing cycle. Resveratrol, with a half-life of approximately 8 to 14 hours for its primary metabolites, maintains some AMPK activity throughout the day. No dose-separation window eliminates this overlap.

10

Lower Doses, Lower Risk

If a patient and prescriber decide together that resveratrol is worth trialing, starting at the lowest available dose (150 mg/day) and monitoring fasting glucose for four weeks before any dose increase is a reasonable approach. Dose escalation above 500 mg/day should prompt a review of the Tresiba dose to see whether a modest basal insulin reduction is warranted.

The HealthRX clinical team uses a four-step framework for evaluating supplement additions in patients on basal insulin therapy:

1. Classify the interaction type (pharmacokinetic, pharmacodynamic, or both).
2. Quantify the expected glucose delta from the supplement at the intended dose using published RCT data.
3. Compare that delta against the patient's current fasting glucose buffer (distance between mean fasting glucose and 70 mg/dL).
4. Set a monitoring schedule proportional to the risk: weekly fasting glucose logs for four weeks at low doses; daily logs for patients at higher doses or with A1c already near target.

This framework is not a replacement for individualized clinical judgment, but it gives prescribers and patients a structured way to weigh the decision rather than defaulting to a blanket prohibition or an uninformed approval.

Monitoring Recommendations for Patients Already Taking Both

Glucose Targets and Check Frequency

If you are already taking resveratrol with Tresiba before speaking with your prescriber, do not abruptly stop either without medical guidance. Stopping insulin abruptly is dangerous in type 1 diabetes and can cause significant hyperglycemia in type 2 diabetes.

Check fasting glucose every morning for at least two weeks and log the results. The ADA 2024 target for most non-pregnant adults is a fasting glucose of 80 to 130 mg/dL and a peak postprandial glucose below 180 mg/dL. If fasting readings consistently fall below 90 mg/dL, contact your prescriber: a Tresiba dose reduction may be appropriate.

11

Signs of Hypoglycemia to Watch For

Symptoms warranting immediate glucose testing include: shakiness, sweating without exertion, sudden hunger, confusion, blurred vision, and heart racing. A reading below 70 mg/dL (or below 54 mg/dL for level 2 hypoglycemia per the ADA/EASD definition) requires treatment with 15 to 20 grams of fast-acting glucose and a repeat check in 15 minutes.

A1c Review

Request an A1c at your next quarterly visit if you have started resveratrol. A drop of more than 0.5 percentage points in three months, in the absence of other medication changes, is a signal to revisit whether Tresiba dosing needs adjustment.

What to Tell Your Prescriber Before Starting Resveratrol

Be specific about the product you intend to use. Resveratrol supplements vary enormously in dose and formulation. A 150 mg trans-resveratrol capsule is pharmacologically different from a 1,000 mg "resveratrol complex" that also contains quercetin and grape seed extract, both of which have their own glucose-lowering signals.

Tell your prescriber:

• The exact brand, dose, and formulation you plan to take.
• Your current Tresiba dose and your most recent A1c.
• Any other medications you take that are metabolized by CYP3A4 or CYP2C9.
• Whether you are postmenopausal, since the estrogenic component of resveratrol is more relevant in that population.

Your prescriber may choose to reduce your Tresiba dose by 10 to 20% prophylactically if you are already near glycemic target, or they may recommend against resveratrol entirely based on your individual profile.

Special Populations and Cautions

Type 1 Diabetes

Patients with type 1 diabetes depend entirely on exogenous insulin for survival. Any supplement that increases insulin sensitivity without a corresponding reduction in the exogenous insulin dose can trigger serious hypoglycemia. The margin for error is smaller in type 1 than in type 2, and the benefit-risk ratio for resveratrol is less favorable in this population.

Renal Impairment

Insulin requirements typically decrease as renal function declines, because the kidney clears approximately 25 to 40% of circulating insulin. A patient with an eGFR below 60 mL/min/1.73 m2 who adds resveratrol to Tresiba is at compounded hypoglycemia risk from two directions: reduced insulin clearance and resveratrol's additive glucose-lowering effect.

12

Pregnancy

Resveratrol is not recommended during pregnancy. Animal studies have shown adverse fetal outcomes at high doses. Because insulin requirements change substantially across trimesters, adding an unvalidated glucose-lowering supplement during pregnancy introduces unnecessary risk. The FDA has not evaluated resveratrol for safety in pregnancy.

Summary of Clinical Guidance

Resveratrol is not categorically contraindicated with Tresiba, but the combination carries a meaningful, dose-dependent hypoglycemia risk driven primarily by additive pharmacodynamic effects on blood glucose regulation. The pharmacokinetic interaction (CYP3A4 and CYP2C9 inhibition) is less relevant to insulin degludec itself but matters for co-administered medications. Dose separation does not reduce the pharmacodynamic overlap.

Patients who want to trial resveratrol while on Tresiba should: inform their prescriber before starting, begin at the lowest available dose (150 mg/day), monitor fasting glucose daily for four weeks, and treat any fasting reading below 70 mg/dL as a signal requiring clinical contact.

The ADA 2024 Standards of Care do not endorse resveratrol as adjunct diabetes therapy, and no large randomized trial has evaluated resveratrol specifically in patients on ultra-long-acting insulin analogs. At a fasting glucose target of 80 to 130 mg/dL with Tresiba, even a 5 mg/dL additive reduction from a 500 mg/day resveratrol dose brings many patients close to the hypoglycemia threshold.